Oryzon Genomics S.A (ORYZF PINK) stock market data APIs
$3.6038
0(0%)
as of February 13, 2026
Try our APIs with
free plan!
Oryzon Genomics S.A Financial Data Overview
Price chart is built with
Anychart
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system) disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases; and ORY-4001, a selective HDAC-6 inhibitor for the treatment of neurological disorders, such as Charcot-Marie-Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and others. The company was incorporated in 2000 and is based in Cornellà de Llobregat, Spain.
Prev. Close
3.6038
Open
3.6038
High
3.6038
Low
3.6038
52 wk Range
1.575-4.375
Market Cap
247 M
Shares Outstanding
78 853 K
Revenue
8 634 K
EPS
0.0052
Beta
0.364
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Oryzon Genomics S.A data using free add-ons & libraries
Get Oryzon Genomics S.A Fundamental Data
Oryzon Genomics S.A Fundamental data includes:
- Net Revenue: 8 634 K
- EBITDA: -8 523 023
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-22
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Oryzon Genomics S.A News
New
3 European Growth Companies With Insider Ownership Up To 23%
As the European markets show resilience with the STOXX Europe 600 Index ending higher, driven by robust economic data and earnings results, investors are increasingly focusing on companies that demons...
European Growth Companies With High Insider Ownership December 2025
As European markets show signs of steady economic growth and benefit from looser monetary policies, the pan-European STOXX Europe 600 Index has risen by 1.60%, reflecting a positive sentiment across m...
Discover European Growth Companies With High Insider Ownership
In recent weeks, European markets have shown resilience, with the pan-European STOXX Europe 600 Index rising by 1.77% amid relief over the reopening of the U.S. federal government, though tempered by ...
High Growth Tech Stocks To Watch In October 2025
Amid a volatile global market landscape, U.S. stocks have recently rebounded following a week of substantial fluctuations, buoyed by easing trade tensions and dovish signals from the Federal Reserve. ...
Get Oryzon Genomics S.A fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
